Barry, OppHub America Desk · · Source: yahoo-tickers-tape-movers
Eli Lilly Stock Outperforms S&P 500 on Growth
- Watch as it continues to demonstrate robust revenue and growth, outperforming the broader market and signaling strong operational execution. - Investors may consider for its consistent financial performance and market-leading position within the pharmaceutical sector.
Based on reporting from yahoo-tickers-tape-movers.
Eli Lilly (NYSE:LLY) has significantly outperformed the S&P 500 over the past six months, driven by robust revenue and earnings growth. The pharmaceutical giant has demonstrated strong annualized revenue and EPS expansion, indicating sustained momentum in its business operations and profitability.
Market context for this story
As of: Regular HoursLoading quotes…
Informational only — not investment advice. Full markets →
$SPYSPDR S&P 500 ETF
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/SPY and related $LLY. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
Eli Lilly (NYSE:LLY) has posted substantial gains, outperforming the broader market with a 15.4% rise over the last six months, compared to the S&P 500's 11.6% gain. This outperformance is underpinned by impressive financial metrics. The company has achieved a 24.4% annualized revenue growth over the past five years. Furthermore, Eli Lilly's adjusted operating margin has expanded by 18.7 percentage points in the last two years, reaching a trailing 12-month margin of 44.6%. Earnings per share (EPS) have also shown strong growth, with a 31.4% compounded annual growth rate over the last five years, outpacing its revenue growth and signaling enhanced profitability on a per-share basis.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
- Watch as it continues to demonstrate robust revenue and growth, outper
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: August 28, 2026 at 2:31 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
pharmaceutical growth
Eli Lilly's business is growing very fast, making its stock worth more than the general market. People who invest money care because consistent profit growth usually means a healthy, rewarding company.
What changed
Eli Lilly posted significant stock outperformance over the S&P 500 backed by strong multi-year revenue and margin expansion.
Who wins / who loses
Pharmaceutical leaders with high-demand products win, while slower-growing healthcare peers lag behind.
Time horizon
Think in terms of the next few months.
Confidence & best fit
medium confidence · Long-term investor
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $LLYWatch — track, don’t rush
The main company in the story is growing its sales and profits at an impressive rate.
View $LLY chart → · End-of-day delayed data
Peer
- $NVOWatch — track, don’t rush
Another giant drug company that sells similar popular medicines.
View $NVO chart → · End-of-day delayed data
Avoid / trap
- $PFEStay away — for now
An older drug maker that is not growing as fast right now.
View $PFE chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Direction: bullish · Style: Debit spread (defined risk) · Level: intermediate
Beginners should skip options here; buying shares directly is simpler and safer.
Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Research emerging biotech suppliers and contract manufacturers benefiting from pharmaceutical expansions.
What would break this thesis
- Unexpected regulatory delays, major clinical trial failures, or a broader macroeconomic downturn affecting growth stocks.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).